{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:53:48Z","timestamp":1766516028325,"version":"3.40.5"},"reference-count":35,"publisher":"Termedia Sp. z.o.o.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reumatologia"],"abstract":"<jats:p>A triad of symptoms characterises Felty's syndrome: seropositive rheumatoid arthritis (RA), splenomegaly and neutropenia. The treatment of Felty's syndrome is based on using classic synthetic and biological disease-modifying drugs (DMARDs). In this article, we present a case of a patient with Felty's syndrome who was treated with biologic treatment. A systematic search of the literature on the electronic medical database was conducted.\nThe drugs from the DMARD group, despite reducing the activity of the disease, may cause significant clinical complications. It is important to know about the diagnosis, differentiation and treatment of neutropenia and the prevention of febrile neutropenia. The article discusses the current therapeutic possibilities using both classical and biologic DMARDs.<\/jats:p>","DOI":"10.5114\/reum\/167472","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T10:30:57Z","timestamp":1689762657000},"page":"213-218","source":"Crossref","is-referenced-by-count":4,"title":["Biological treatment in Felty's Syndrome with profound neutropenia"],"prefix":"10.5114","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2246-8611","authenticated-orcid":false,"given":"Krzysztof","family":"Proc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4523-9272","authenticated-orcid":false,"given":"Marta","family":"Madej","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9999-0267","authenticated-orcid":false,"given":"Piotr","family":"Wiland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6332-8714","authenticated-orcid":false,"given":"Agata","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3061","published-online":{"date-parts":[[2023,7,2]]},"reference":[{"key":"ref-908241","doi-asserted-by":"publisher","DOI":"10.2174\/1874312901408010129"},{"key":"ref-908242","unstructured":"Patel R, Akhondi H. Felty\u2019s syndrome. In: StatPearls. Treasure Island (FL): StatPearls Publishing 2021."},{"key":"ref-908243","unstructured":"Urbanowicz I, Korycka-Wo\u0142owiec A, Wo\u0142owiec D. A patient with an abnormal leukocyte count in a primary care clinic. In: Hematology. Wo\u0142owiec D, Hus I, Korycka-Wo\u0142owiec A (ed.). Wyd. Lekarskie PZWL, Warszawa 2017."},{"key":"ref-908244","doi-asserted-by":"publisher","DOI":"10.3324\/haematol"},{"key":"ref-908245","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/37.8.908"},{"key":"ref-908246","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.08.008"},{"key":"ref-908247","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032110"},{"key":"ref-908248","doi-asserted-by":"crossref","unstructured":"Kimura Y, Yoshida S. Successful abatacept treatment for Felty\u2019s syndrome in a patient with rheumatoid arthritis. Mod Rheumatol Case Rep 2020; 4: 168\u2013170, DOI: 10.1080\/ 24725625.2020.1717740.","DOI":"10.1080\/24725625.2020.1717740"},{"key":"ref-908249","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-020-02054-4"},{"key":"ref-908250","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-021-02802-9"},{"key":"ref-908251","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04588-3"},{"key":"ref-908252","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2012.01.013"},{"key":"ref-908253","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e318164bf32"},{"key":"ref-908254","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2017"},{"key":"ref-908255","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2008.02.018"},{"key":"ref-908256","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.078915"},{"key":"ref-908257","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-014-1380-5"},{"key":"ref-908258","doi-asserted-by":"publisher","DOI":"10.1097\/01.rhu.0000200326.17729.76"},{"key":"ref-908259","doi-asserted-by":"crossref","unstructured":"Heylen L, Dierickx D, Vandenberghe P, Westhovens R. Targeted therapy with rituximab in Felty\u2019s syndrome: a case report. Open Rheumatol J 2012; 6: 312\u2013314, DOI: 10.2174\/ 1874312901206010312.","DOI":"10.2174\/1874312901206010312"},{"key":"ref-908260","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000440"},{"key":"ref-908261","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.025643"},{"key":"ref-908262","doi-asserted-by":"publisher","DOI":"10.1097\/01.RHU.0000450285.43361.ab"},{"key":"ref-908263","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.077966"},{"key":"ref-908264","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000175"},{"key":"ref-908265","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"ref-908266","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2004.05.002"},{"key":"ref-908267","doi-asserted-by":"publisher","DOI":"10.2147\/IMCRJ.S365004"},{"key":"ref-908268","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2013.1779"},{"key":"ref-908269","unstructured":"Talip F, Walker N, Khan W, Zimmermann B. Treatment of Felty\u2019s syndrome with leflunomide. J Rheumatol 2001; 28: 868\u2013870."},{"key":"ref-908270","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheumatol.2014.026"},{"key":"ref-908271","unstructured":"The European public assessment report (EPAR) for Enbrel. https:\/\/www.ema.europa.eu\/."},{"key":"ref-908272","unstructured":"The European public assessment report (EPAR) for Erelzi. https:\/\/www.ema.europa.eu\/."},{"key":"ref-908273","doi-asserted-by":"crossref","unstructured":"Brunasso AM, Massone C. Thrombocytopenia associated with the use of anti-tumor necrosis factor-alpha agents for psoriasis. J Am Acad Dermatol 2009; 60: 781\u2013785, DOI: 10.1016\/ j.jaad.2008.12.001.","DOI":"10.1016\/j.jaad.2008.12.001"},{"key":"ref-908274","doi-asserted-by":"publisher","DOI":"10.32383\/farmpol\/116292"},{"key":"ref-908275","doi-asserted-by":"crossref","unstructured":"Hazenberg BP, Van Leeuwen MA, Van Rijswijk MH, et al. Correction of granulocytopenia in Felty\u2019s syndrome by granulocyte-macrophage colony-stimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis. Blood 1989; 74: 2769\u20132770.","DOI":"10.1182\/blood.V74.8.2769.bloodjournal7482769"}],"container-title":["Rheumatology"],"original-title":[],"link":[{"URL":"https:\/\/reu.termedia.pl\/pdf-167472-92215","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reu.termedia.pl\/pdf-167472-92215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T10:33:06Z","timestamp":1689762786000},"score":1,"resource":{"primary":{"URL":"https:\/\/reu.termedia.pl\/Biological-treatment-in-Felty-s-Syndrome-with-profound-neutropenia,167472,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,2]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"alternative-id":["167472"],"URL":"https:\/\/doi.org\/10.5114\/reum\/167472","relation":{},"ISSN":["0034-6233","2084-9834"],"issn-type":[{"type":"print","value":"0034-6233"},{"type":"electronic","value":"2084-9834"}],"subject":[],"published":{"date-parts":[[2023,7,2]]}}}